WO2017186954A1 - Procédé d'amélioration de la vitesse et de la capacité d'endurance - Google Patents

Procédé d'amélioration de la vitesse et de la capacité d'endurance Download PDF

Info

Publication number
WO2017186954A1
WO2017186954A1 PCT/EP2017/060290 EP2017060290W WO2017186954A1 WO 2017186954 A1 WO2017186954 A1 WO 2017186954A1 EP 2017060290 W EP2017060290 W EP 2017060290W WO 2017186954 A1 WO2017186954 A1 WO 2017186954A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
species
weight
months
health food
Prior art date
Application number
PCT/EP2017/060290
Other languages
English (en)
Inventor
Saad Harti
Jiawei Liu
Michel CHRETIENNE
Cécile BERNIER
Original Assignee
Legacy Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Ltd filed Critical Legacy Healthcare Ltd
Publication of WO2017186954A1 publication Critical patent/WO2017186954A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention concerns a health food supplement or pharmaceutical composition for the improvement of speed and endurance capacity.
  • Maintaining one's muscles in a healthy state is critical for physical performance, and overall wellbeing. Physical activity has been promoted as an important aspect of a healthy lifestyle. This situation leads to what is referred to as 'locomotive syndrome'. Prolonged muscle disuse can lead to loss of muscle tissue and reduced muscle strength. Muscle disuse can be due to immobilization, injury, disease, bed rest, hospitalization, weightlessness, and the like. The loss of muscle tissue and muscle strength is generally exacerbated by aging. This loss of muscle tissue and muscle strength may impair a subject's mobility, which discourages physical activity and leads to even further loss of muscle tissue. Exercise may not always be feasible, especially if the subject is elderly with significant degenerative conditions, recovering from serious illness, or has been immobilized for an extended period of time. Therefore, nutritional interventions that can prevent or slow the loss of muscle strength before, during and after the period of muscle disuse can be highly desirable.
  • the present invention provides a health food supplement and a pharmaceutical composition for the improvement of speed and/or for stimulating muscle strength and/or improving endurance capacity comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the invention in one aspect is a method for the improvement of speed and endurance capacity comprising the administration of a health food supplement comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the invention consists in a health food supplement and/or a composition, in particular a pharmaceutical composition, comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in the treatment and/or prevention of frailty conditions in sick or elderly patients.
  • Fig. 1 shows the effects of the composition administration on speed.
  • administration should be understood to comprise at least one of: a) providing the composition to a subject; and b) the act of consuming the pharmaceutical composition or the health food supplement. Unless otherwise indicated, the composition is administered to the subject orally or enterally.
  • muscle disuse refers to a substantial lack of activity of a particular muscle, muscle type, or muscle group due to partial or full immobilization, injury, illness, bed rest, ageing, hospitalization, weightlessness, and the like.
  • muscle recovery refers to use of a particular muscle, muscle type, or muscle group, after a period of muscle disuse. Muscle recovery may include gentle stretching, contraction, and movement of the muscles and structured rehabilitation after the muscles have been inactive. Muscle recovery may, but does not necessarily, include strenuous exercise, including weight- bearing, resistance, walking (gait speed) and cardiovascular exercise, to quickly rebuild and increase muscle mass and muscle strength.
  • health food supplement refers to products in various forms including, but not limited to, liquids, solids, powders, semi-solids, semi-liquids, nutritional supplements, and any other food product known in the art.
  • period of muscle disuse refers to the interval of time that the muscle or muscles are substantially inactive.
  • a period of muscle disuse is at least 4 hours of substantially continuous muscle inactivity.
  • occasional short intervals of mild muscle use such as sitting up in bed or walking only a short distance (less than 100 meters) may be included within a period of muscle disuse. This period may be about 4 hours, about 8 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about one week, about two weeks, about one month, about two months, about three months, about six months, about nine months, about twelve months, or longer than twelve months in duration.
  • subject refers to a mal, including but not limited to, a human, a domesticated farm animal (e.g., cow, horse, pig, or chicken), or a pet (e.g., dog or cat). In certain preferred embodiments, the subject is a human.
  • a domesticated farm animal e.g., cow, horse, pig, or chicken
  • a pet e.g., dog or cat.
  • the subject is a human.
  • 'performance' and 'exercise performance' refers to movements of a subjects that can be maintained for the duration of an exercise to achieve a desired result of strength, speed and endurance.
  • the present invention provides a health food supplement or a pharmaceutical composition for improvement of speed and/or for stimulating muscle strength and/or improving endurance capacity comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the active ingredients are administered in effective doses.
  • effective dose is well understood in the art. In pharmacology, effective dose is the median dose that produces the desired effect of a drug. The effective dose is often determined based on analyzing the dose-response relationship specific to the drug.
  • the health food supplement or pharmaceutical composition comprises from 30% to 80% by weight of an extract of Allium species, from 1 .5% to 25% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • the health food supplement or pharmaceutical composition comprises from 30% to 80% by weight of an extract of Allium species, from 1 .5% to 25% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1 .0% to 8.0% by weight of sodium chloride and from 15% to 50% by weight of an excipient, additive, adjuvant and the like based on the total weight of the composition. Excipient, additives, adjuvants and the like for use in such compositions are known to the skilled person and do not require elucidation here.
  • the invention in one aspect consists of a method for stimulating the muscle strength and/or for improving the speed comprising the administration of a pharmaceutical composition or a health food supplement comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the supplement or composition is orally administered to the subject in a liquid solid or liquid carrier.
  • the administrated composition or supplement contains from 30% to 80% by weight of an extract of Allium species, from 1 .5% to 25% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • the composition or the supplement is administered daily or weekly for a period of at least one month, preferably several months or beyond (long-term use).
  • the composition or the supplement is used after a period of muscle disuse or in a situation that requires a booster treatment to increase muscle strength and tone.
  • the invention consists in a composition comprising as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in the treatment and/or the prevention of frailty conditions in a sick or an elderly patient.
  • the present invention consists in a method of treating and/or preventing frailty conditions comprising administering to the subject an effective amount of a composition comprising from 30% to 80% by weight of an extract of Allium species, from 1 .5% to 25% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • Frailty is a clinical syndrome with symptoms as low body weight due to unintentional weight loss, exhaustion, weakness, slow walking and low physical activity. Frailty is characterized by a decreased reserve and resistance to stressors, in turn resulting from cumulative decline across multiple physiologic systems, and causing a vulnerability to adverse outcomes. A major aspect of frailty is that it affects muscle mass and strength. Some clinical investigation has been done on the effect of various treatments on individual frailty symptoms. This includes, e.g., the effect of anabolic steroids on muscle mass, which is well known to the skilled person.
  • the supplement or composition according to the present invention will generally be administered daily or weekly for a period of at least one month, preferably for several months, generally at least 3 months to 12 months, preferably for 4 to 8 months, and most preferably for 6 months, or for long-term use.
  • the supplement or composition according to the invention can also be used for the prevention of frailty in patients that are prone to become frail, in particular after an hospitalization.
  • the supplement or composition comprising an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species is prepared as indicated in patent application WO2008/1 13912. It involves the preparation of a master solution containing the extracts of Allium species and Citrus species and then mixing this solution either with an extract of Paullinia species and an extract of Theobroma species.
  • the method is characterized in that the master solution is prepared by picking, cleaning and milling the Allium and the Citrus, macerating for several hours in alcohol and filtering, then adjusting the alcoholic extract and mixing with the other ingredients.
  • a recommended procedure is to prepare the master solution from the constituents, by picking, cleaning and milling the Allium and the Citrus, mixing with 96° alcohol, macerating in the cold for 60 hours, filtering the master solution through 0.22-micron filters to give a water-alcohol extract with a low content of particles.
  • the ethanol is then evaporated, glycerin and preservatives are added.
  • This master solution is then treated, by simple mixing, either with the extracts (atomised or not) of Paullinia species and Theobroma species.
  • the health food supplement or pharmaceutical composition of the present invention is formulated into a suitable composition and then, in accordance with the methods disclosed herein, administered to a subject in a form adapted to the chosen route of administration.
  • the compositions disclosed herein include, but are not limited to, those suitable for oral administration.
  • oral administration typically refers to oral consumption, but may also include other forms of enteral administration (i.e., administration through the digestive track).
  • Other forms of enteral administration suitable for use with the methods disclosed herein include nasogastric, gastric, or jejunal intubation.
  • the health food supplement or composition disclosed herein are formulated as medicaments.
  • suitable forms of the composition as a medicament include caplets, tablets, pills, capsules, chewable tablets, quick dissolve tablets, effervescent tablets, solutions, suspensions, emulsions, multi-layer tablets, bi- layer tablets, soft gelatin capsules, hard gelatin capsules, lozenges, chewable lozenges, beads, granules, particles (including particles enabling sustained release), microparticles, sachets, and combinations thereof.
  • the composition may be in the form of a powder or liquid concentrate packaged in a sachet, the contents of which may be added to water or other potable liquid to form a beverage.
  • the health food supplement or composition according to the invention is formulated as a nutritional composition.
  • compositions disclosed herein may comprise one or more compounds selected from human milk, prebiotics, probiotics and combinations thereof.
  • compositions used according to the invention are those containing approximately 66% by weight of an extract of Allium cepa, approximately 9% by weight of an extract of Citrus lemon, approximately 0.1 1 % by weight of an extract (atomized or not) of Paullinia cupana and approximately 0.1 1 % by weight of an extract (atomized or not) of Theobroma cacao, based on the total weight of the four active ingredients.
  • the health food supplement or composition is administered in particular orally in accordance with the present disclosure to a subject as needed to preserve muscle strength during a period of muscle disuse or muscle recovery.
  • the compositions may be administered to a subject solely during the period of muscle disuse or solely during the period of muscle recovery. However, to preserve muscle strength more fully, it is generally desirable to administer the present supplement or composition to the subject before, during the period of muscle disuse and the period of muscle recovery.
  • the subject may also be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse resulting from a portion of the subject's body being immobilized.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse as a result of a severe illness.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs while recovering from surgery.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs during hospitalization.
  • the subject may be a child, a pregnant woman, or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs during prolonged bed rest.
  • the subject may be an adult or older adult who is susceptible loss of muscle strength due to muscle disuse resulting from prolonged inactivity.
  • the subject may be an elderly, having an age of 60 or older.
  • the subject may be a child or an adult who is interested in preventing loss of muscle strength.
  • the subject may also be interested to stimulate its muscle strength or to increase its running speed.
  • the compositions can be administered to subjects during periods of muscle disuse.
  • the compositions disclosed herein are administered to the subject when the period of muscle disuse lasts at least 4 hours.
  • compositions are administered to the subject when the period of muscle disuse lasts from about 4 hours to about 72 hours, including from about 4 hours to about 48 hours, including from about 4 hours to about 24 hours, including from about 4 hours to about 12 hours, including from about 8 hours to about 72 hours, including from about 8 hours to about 48 hours, including from about 8 hours to about 24 hours, including from about 12 hours to about 72 hours, including from about 12 hours to 48 hours, and including from about 12 hours to about 24 hours.
  • compositions are administered to the subject when the period of muscle disuse lasts from about 24 hours to about 36 months, including from about 24 hours to about 24 months, including from about 24 hours to about 12 months, including from about 24 hours to about 6 months, including from about 24 hours to about 3 months, including from about 24 hours to about 2 months, including from about 24 hours to about 1 month, including from about 24 hours to about 2 weeks, including from about 24 hours to about 1 week, including from about 48 hours to about 36 months, including from about 48 hours to about 24 months, including from about 48 hours to about 12 months, including from about 48 hours to about 6 months, including from about 48 hours to about 3 months, including from about 48 hours to about 2 months, including from about 48 hours to about 1 month, including from about 48 hours to about 2 weeks, including from about 48 hours to about 1 week, including from about 72 hours to about 12 months, including from about 72 hours to about 6 months, including about 72 hours to about 3 months, including from about 72 hours to about 1 month, including from about 72 hours to 2 weeks, including from about 72 hours to about 36 months, including
  • compositions disclosed herein can be administered to a subject for a period of muscle disuse lasting at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 1 week, at least 10 days, at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, at least 12 months, at least 24 months, at least 36 months, or for more than 36 months.
  • compositions can be administered to subjects during periods of muscle disuse.
  • compositions can be administered to subjects to improve their muscle strength.
  • the supplement or composition according to the invention may normally contain from 0.4 to 1000 mg, preferably from 2 to 400 mg, of active ingredients as defined above.
  • the respective amounts are preferably:
  • mice have received, by oral route, a treatment containing:
  • composition A (hereafter composition A).
  • mice split in 2 groups: 5 taking the composition A and 5 taking the placebo Day 0-7: acclimatization
  • mice received ad libitum access to water and chow.
  • Figure 1 represents the Mean Dark Cycle Activity (evaluation of speed).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un complément alimentaire de santé ou une composition pharmaceutique destinés à être utilisés pour améliorer la vitesse et/ou stimuler la force musculaire et/ou améliorer la capacité d'endurance d'un sujet, comprenant comme principe actif un extrait d'espèce Allium, un extrait d'espèce Citrus et un extrait d'espèce Paullinia et un extrait d'espèce Theobroma. Le complément alimentaire de santé et la composition pharmaceutique selon l'invention sont particulièrement utiles pour le traitement et/ou la prévention d'états de faiblesse d'origine quelconque.
PCT/EP2017/060290 2016-04-28 2017-04-28 Procédé d'amélioration de la vitesse et de la capacité d'endurance WO2017186954A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328664P 2016-04-28 2016-04-28
US62/328,664 2016-04-28

Publications (1)

Publication Number Publication Date
WO2017186954A1 true WO2017186954A1 (fr) 2017-11-02

Family

ID=58671628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/060290 WO2017186954A1 (fr) 2016-04-28 2017-04-28 Procédé d'amélioration de la vitesse et de la capacité d'endurance

Country Status (1)

Country Link
WO (1) WO2017186954A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021224455A1 (fr) * 2020-05-07 2021-11-11 Legacy Healthcare (Switzerland) Sa Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications
US20150080328A1 (en) * 2012-03-23 2015-03-19 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
WO2015067759A1 (fr) * 2013-11-08 2015-05-14 Legacy Healthcare Ltd Procédé de gestion du cancer et traitement de comorbidités du cancer
WO2015151066A1 (fr) * 2014-04-04 2015-10-08 Polifenoles Naturales, S.L. Traitement de la sarcopénie au moyen d'ecdystéroïdes
CA2946825A1 (fr) * 2014-04-28 2015-11-05 Suntory Holdings Limited Inhibiteur de l'atrophie musculaire contenant un glycoside de quercetine
US20150352172A1 (en) * 2013-01-03 2015-12-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications
US20150080328A1 (en) * 2012-03-23 2015-03-19 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
US20150352172A1 (en) * 2013-01-03 2015-12-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
WO2015067759A1 (fr) * 2013-11-08 2015-05-14 Legacy Healthcare Ltd Procédé de gestion du cancer et traitement de comorbidités du cancer
WO2015151066A1 (fr) * 2014-04-04 2015-10-08 Polifenoles Naturales, S.L. Traitement de la sarcopénie au moyen d'ecdystéroïdes
CA2946825A1 (fr) * 2014-04-28 2015-11-05 Suntory Holdings Limited Inhibiteur de l'atrophie musculaire contenant un glycoside de quercetine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUTIERREZ-SALMEAN GABRIELA ET AL: "Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentia", THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 25, no. 1, 2014, pages 91 - 94, XP028794875, ISSN: 0955-2863, DOI: 10.1016/J.JNUTBIO.2013.09.007 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021224455A1 (fr) * 2020-05-07 2021-11-11 Legacy Healthcare (Switzerland) Sa Composition pour renforcement du système immunitaire chez l'homme et l'animal en vue de l'acquisition d'une immunité globale
FR3109881A1 (fr) * 2020-05-07 2021-11-12 Legacy Healthcare (Switzerland) Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
CN115666525A (zh) * 2020-05-07 2023-01-31 传世医疗(瑞士)有限公司 用于增强人和动物免疫系统以获得多种免疫的组合物
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Similar Documents

Publication Publication Date Title
US11123407B2 (en) Nutritional composition for treating or preventing impaired mobility
JP5662492B2 (ja) 抗炎症製剤
TWI565420B (zh) 使用β－羥基－β－甲基丁酸鹽改善腦部發育及認知功能的方法
JPH07507569A (ja) ヒトの窒素保持の促進方法
JP5191955B2 (ja) 粘膜免疫調節剤並びにその用途
WO2017186954A1 (fr) Procédé d'amélioration de la vitesse et de la capacité d'endurance
JP5281268B2 (ja) 筋力向上剤
US20230201255A1 (en) Composition comprising cinnamaldehyde and zinc to improve swallowing
WO2016044167A1 (fr) Procédés d'accroissement de la force musculaire et de la mobilité chez des sujets subissant une inactivité physique significative à l'aide d'acide gamma-linolénique
CN116077474A (zh) 使用肉桂醛增加能量消耗的方法和组合物
JP6368368B2 (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
JP6360172B2 (ja) チグリンアルデヒドを使用する組成物及び方法
Subramaniam et al. Change in salivary pH following use of homeopathic medicines: a preliminary study
CN107809916A (zh) 用于治疗营养不良的组合物和方法
JP6762007B2 (ja) 変形性関節症予防用組成物、変形性関節症予防用食品組成物、変形性関節症予防用食品添加物及び変形性関節症予防用医薬
JP7398192B2 (ja) 抗ストレス用組成物
Rosen “The Gripe”: An integrative approach to infant colic
JP2008031080A (ja) 脂質利用促進組成物
JPH06345660A (ja) ナトリウム吸収阻害剤、ナトリウム吸収阻害飲食物および動物用飲食物
TW202126297A (zh) 肌肉量之降低抑制、降低預防、維持、回復或增加用組成物
CN118303636A (en) Functional food for improving parkinsonism
KR20120074352A (ko) 아파민을 유효성분으로 포함하는 동맥경화 예방 및 치료용 약학 조성물
Bauer et al. D. Drugs
JP2005154401A (ja) 便消臭組成物
JP2004337107A (ja) 動物用夜鳴き改善剤及び動物用夜鳴き改善食品

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17721609

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17721609

Country of ref document: EP

Kind code of ref document: A1